Want to see IN:BIOCON full AI Analyst Report?

Biocon Limited (BIOCON) Price & Analysis

16 Followers

BIOCON Stock Chart & Stats

₹433.70

₹2.60(0.60%)

At close: Jul 27 4:00 PM EDT

₹433.70

₹2.60(0.60%)

Day’s Range― - ―

52-Week Range₹331.00 - ₹447.00

Previous CloseN/A

Volume2.57M

Average Volume (3M)208.50K

Market Cap

₹693.01B

Enterprise Value₹714.88K

Total Cash (Recent Filing)₹38.83B

Total Debt (Recent Filing)₹154.34B

Price to Earnings (P/E)152.6

Beta0.71

Next Earnings

Aug 05, 2026

EPS Estimate

1.01

Next Dividend Ex-DateN/A

Dividend Yield0.12%

Share Statistics

EPS (TTM)2.79

Shares Outstanding1,629,694,100

10 Day Avg. Volume177,351

30 Day Avg. Volume208,504

Financial Highlights & Ratios

PEG Ratio-1.92

Price to Book (P/B)1.45

Price to Sales (P/S)2.92

P/FCF Ratio-94.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)7.92

Revenue Forecast (FY)₹199.39B

Bulls Say, Bears Say

Bulls Say

Diversified Biopharma Business ModelBiocon’s mix of biosimilars, generics and biologics manufacturing services provides multiple durable revenue streams across diabetes, oncology and immunology. This integrated model reduces single-product dependency, supports scale economies, and enables partner-led commercialization over the medium term.

Consistent Multi-year Revenue GrowthSustained top-line expansion (~10.9% recent growth) reflects underlying demand and commercial traction across segments. Durable revenue growth increases capacity to absorb R&D and manufacturing investment, supports long-term scale advantages, and provides runway to recover margins if operational levers are executed.

Improving Leverage / Capital StructureA markedly lower debt-to-equity ratio strengthens financial flexibility and reduces interest burden versus prior years. Improved leverage lowers refinancing risk, preserves capacity for strategic investments or partnerships, and enhances resilience to cyclical pressures over the next several quarters.

Bears Say

Sharp Margin CompressionA material decline in gross and net margins signals either pricing pressure, adverse product mix, or higher costs. Persistent margin compression undermines sustainable earnings power, reduces ability to self-fund R&D and capex, and raises the bar for operational improvements to restore long-term profitability.

Weak Cash Generation And Negative FCFNegative free cash flow and deteriorating operating cash flow indicate earnings are not converting into durable liquidity. This raises dependence on external financing or asset sales to fund operations and growth, constraining strategic flexibility and elevating funding risk over the coming quarters.

Very Low Return On EquityROE near 1.1% reflects poor capital efficiency—shareholders’ capital is generating minimal returns. Unless profitability and margins improve structurally, low ROE limits investor support and suggests the company may struggle to justify reinvestment without meaningful operational or commercial turnaround.

Biocon Limited News

Biocon Wins Health Canada Approval for Yesintek Ustekinumab Autoinjector Pen

Biocon Limited ( ($IN:BIOCON) ) has issued an announcement. Biocon’s Canadian subsidiary has received Health Canada’s Notice of...

5d ago

Biocon makes Biocon Biologics a wholly owned unit via share swap

Biocon Limited ( ($IN:BIOCON) ) has provided an update. Biocon Limited has acquired 11,536,956 equity shares of its...

1M ago

Biocon Makes Biocon Biologics Wholly Owned Via Preferential Share Issue

An announcement from Biocon Limited ( ($IN:BIOCON) ) is now available. Biocon Limited has completed the acquisition of...

1M ago

Biocon Closes Insider Trading Window Ahead of June Quarter Results

Biocon Limited ( ($IN:BIOCON) ) has shared an update. Biocon Limited has announced the closure of its trading...

1M ago

Biocon Deepens Malaysia Diabetes Push as Partner Wins MYR 225 Million Insulin Tenders

Biocon Limited ( ($IN:BIOCON) ) just unveiled an announcement. Biocon has reinforced its presence in Malaysia’s diabetes care...

1M ago

Biocon Sets Final Dividend and Outlines TDS Rules for FY 2025-26 Payout

Biocon Limited ( ($IN:BIOCON) ) just unveiled an update. Biocon Limited has informed shareholders that its board has...

1M ago

Biocon Subsidiary Wins Health Canada Nod for Antifungal Micafungin Injection

The latest update is out from Biocon Limited ( ($IN:BIOCON) ). Biocon Pharma Limited, a subsidiary of Biocon...

3M ago

Biocon Seeks Shareholder Nod for Leadership Changes and Preferential Share Issue via E-Voting

The latest update is out from Biocon Limited ( ($IN:BIOCON) ). Biocon Limited has initiated a postal ballot...

3M ago

Biocon Reshapes Board and Governance as It Integrates with Biocon Biologics

Biocon Limited ( ($IN:BIOCON) ) has shared an announcement. Biocon’s board approved the audited standalone and consolidated financial...

3M ago

Biocon Delivers Double-Digit Growth in Q4 as Biosimilars Lead Revenue Gains

Biocon Limited ( ($IN:BIOCON) ) has issued an update. Biocon reported consolidated Q4FY26 total income of Rs 4,569...

3M ago

BIOCON FAQ

What was Biocon Limited’s price range in the past 12 months?

Biocon Limited lowest stock price was ₹331.00 and its highest was ₹447.00 in the past 12 months.

What is Biocon Limited’s market cap?

Biocon Limited’s market cap is ₹693.01B.

When is Biocon Limited’s upcoming earnings report date?

Biocon Limited’s upcoming earnings report date is Aug 05, 2026 which is in 3 days.

How were Biocon Limited’s earnings last quarter?

Biocon Limited released its earnings results on May 07, 2026. The company reported ₹1.2 earnings per share for the quarter, beating the consensus estimate of ₹1.174 by ₹0.026.

Is Biocon Limited overvalued?

According to Wall Street analysts Biocon Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Biocon Limited pay dividends?

Biocon Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.12%. See more information on Biocon Limited dividends here

What is Biocon Limited’s EPS estimate?

Biocon Limited’s EPS estimate is 1.01.

How many shares outstanding does Biocon Limited have?

Biocon Limited has 1,629,694,100 shares outstanding.

What happened to Biocon Limited’s price movement after its last earnings report?

Biocon Limited reported an EPS of ₹1.2 in its last earnings report, beating expectations of ₹1.174. Following the earnings report the stock price went up 0.486%.

Which hedge fund is a major shareholder of Biocon Limited?

Currently, no hedge funds are holding shares in IN:BIOCON

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Biocon Limited

Biocon Limited functions as a biopharmaceutical firm, engaged in the production of pharmaceutical, medicinal chemical, and plant-derived products. Its business activities are organized into distinct segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company dedicates its efforts to crucial therapeutic domains, including diabetes, oncology, immunology, ophthalmology, and bone health disorders. Furthermore, Biocon provides comprehensive services encompassing the discovery, development, and manufacturing of both small and large molecules. With a wide international presence, it caters to customers in roughly 120 nations. Headquartered in Bengaluru, India, Biocon Limited commenced operations in 1978.